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Abstract
The mutations of a complex systemic disease like cancer can be modeled as stuck-at faults in the Boolean
system paradigm. For a class of multiple faults, the fault identification is exceptionally significant under
the incomplete access of all the underlying proteins of the system. A comprehensive linear framework has
been developed in this manuscript to identify the class of faults under a set of homeostatic input conditions.
An algorithm is developed to design new reporters to improve the observability. The other aspect of this
manuscript lies in controlling the manifestation of the mutations, which is the essential objective of systems
medicine research. The primary goal is to synthesize a cocktail of drug molecules (combination therapy)
from a set of existing targeted drugs. The controllability results are included in this paper to understand
the problem formally. An improvement of controllability algorithm is discussed to design new target drugs
if the available drugs fail to accommodate the underlying fault set. The results are presented for Boolean
maps and Boolean control networks. Biological examples are given to highlight the relevant results.
Keywords: Boolean control networks, cancer, inhibitory drugs, semi-tensor product, controllability,
observability.
1 Introduction
The emergence of ‘systems biology’ opens up new frontiers in medicine and biology. One of the major
challenges in modern medical science has been to provide a cure for complex systemic diseases like cancer,
Alzheimer’s, and Parkinson’s, to name a few. Cancer is taken as the model system for the work in this
manuscript. The futility of traditional therapeutic procedures in developing one wonder-drug to cure cancer
has forced physicians to look into targeted combination therapy [1–3]. For the effective efforts towards the
design of optimal combination therapy, it is required to have a reliable modeling scheme of the cancerous
system such that a ‘healthy’ response, ‘proliferating’ response, and ‘post-therapy’ response can be compared
quantitatively. With such modeling scheme, a drug optimization problems can be defined which bring all
these responses quantitatively closer to minimize effects of a disease.
Kauffman [4] stated the possibility of modeling gene interactions with the Boolean network. The
quantized states (ON and OFF) of the gene were represented as 0 and 1 in the logical domain. Since then,
the Boolean modeling style has become famous among researchers [5–7] because of its discrete nature. The
discrete nature helps to keep the computational complexity tractable for biological problems. Therefore,
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Boolean map (BM) and Boolean control network (BCN) have been taken as standard Boolean systems for
modeling gene-regulatory networks in this manuscript.
A detailed study of the biological aspect of cancer was given by [8]. Systemic diseases like cancer begin
with random mutations in somatic cells [8–10] causing faults in the model and alter its desired dynamics.
The altered dynamics of the system often results in an undesirable output vector (disease phenotypes).
Depending on the nature of mutation, these mutations are mapped as different stuck-at faults in the Boolean
systems [11, 12]. These faults can be categorized into three types. If the mutated gene gets deleted or
becomes incapable of transcribing and translating into the protein, the fault is of ‘stuck-at 0’ (sa-0) type.
Sometimes the mutation is such that the folded protein becomes constitutively active in the relevant signaling
pathway. Then, the fault is considered to be of ‘stuck-at 1’ (sa-1) type. The ‘no-fault’ scenario appears
when the mutation does not alter the kinase binding residues of the protein and the wild-type behavior
continues [11]. The available targeted drugs for cancer are mostly small inhibitory molecules capable of
blocking cell signaling in transduction pathways [11]. Hence, the drugs can be modeled as de-novo inputs
to the Boolean system. These drugs control the network behavior; however, the problem of finding suitable
drugs is entirely dependent on the ability to estimate the possible mutations (faults). The detail description
of the mentioned biological terms is given in [8].
With such fault and drug modeling in the Boolean domain, a method to obtain optimal drugs was
chalked out by [11], which showed a promising preliminary result towards predictive combination therapy
design for single fault scenario (SSF). However, the possibility of the number of mutations is arbitrary in a
general biological system. Therefore, methods are required to detect the presence of multiple stuck-at faults
(MSF). Such fault detection problems are NP-complete [13, 14]. An interesting approach to fault analysis
in Boolean networks was given by [15]. However, the assumption of ‘fault sequence’ used by them was
perhaps unnecessary for real biological systems because the timescale of variation in fault vector (via random
mutation) is the order of magnitude higher than the timescale of any fault diagnosis or therapy of the faulty
system. Also, a trajectory-based design is not completely reliable in biological systems, as the experimental
samples are usually collected non-uniformly. There is a possibility of missing certain critical transient states
in such experiments. Li and Wang [16] developed a ‘test set’ design approach for combinational networks
or Boolean maps (BMs). Liu et al. [17] extended this method for multi-valued logical maps. However, both
of these papers did not consider the sequential networks or Boolean control networks (BCNs) which are
considerably more complicated than a BM, especially for the multiple fault detection [12]. Apart from this,
an important class of ‘no-fault’ (absence of a fault) was not considered in [15–17]. All these aspects have
been considered for the work in this manuscript.
Unlike Boolean models, it may not always be possible to fix the specific ‘test patterns’ in the biological
network for the detection of faults (mutations). For this reason, the test set based methods like [16, 18, 19]
may not be used in a real biological scenario. For undetectable faults, an algorithm for improvement in
observability is given in this manuscript. Some earlier aspects of observability problems were considered
in [20–23]. In this manuscript, the optimal drugs are estimated with this fault information. If available
drugs are unable to provide a suitable cure, an improvement in controllability has been suggested which
provide new target locations.
With the above background, the motivation behind the underlying work resides in attempting a unified
model based approach towards the realistic fault identification and intervention problems for the two classes
of Boolean systems, namely the BM and the BCN. The initial results of this work were published in [24].
Note that, the terms of drug (vector) and intervention are used with the same meaning interchangeably in
this paper.
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2 Preliminaries
2.1 Variables in logical domain
Let a logical domain be defined as
L = {True = 1, False = 0}.
Let u be the input variable and y be the output variable. For the logical domain,{u, y} ∈ L. d is a logical
variable for a drug such that d = 1 means the drug is applied and d = 0 means the drug is not applied,
i.e., d ∈ L. f is a ternary variable for a fault with values {sa-1, sa-0, no-fault} which are represented as
f ∈ {−1, 0, 1}.
For α number of primary inputs, the input state (Boolean vector) is defined as U = (u1, . . . , uα),
U ∈ {0, 1}α. Similarly, for β number of primary outputs, the output state is Y ∈ {0, 1}β ; for λ number of
drugs, the drugs state is D ∈ {0, 1}λ; and for γ number of faults, the fault state is F ∈ {−1, 0, 1}γ . The
notations α, β, γ, and λ are used in this same context throughout the manuscript.
2.2 Boolean control network and Boolean map
2.2.1 Boolean control network
A Boolean control network (BCN) [4, 25–27] is a discrete-time, discrete-state, deterministic system. Due to
the presence of a feedback loop, it can be perceived similar to a sequential network in Boolean domain.
Definition 2.1. : A BCN is a uniformly sampled discrete state dynamical system represented as:
X(τ) = Ψ∗
(
U(τ), X(τ − 1)), X(0) = X0,
Y (τ) = Γ∗
(
U(τ), X(τ)
)
,
(1)
where Ψ∗ : {0, 1}α × {0, 1}N → {0, 1}N and Γ∗ : {0, 1}α × {0, 1}N → {0, 1}β are two Boolean operators
governing the dynamics of the BCN. N is the number of feedback variables, τ ∈ Z+ is a non-negative discrete
time index, and the feedback state X(τ) ∈ {0, 1}N . The input state U(τ) ∈ {0, 1}α, and the output state
Y (τ) ∈ {0, 1}β are the Boolean vectors as defined in Section 2.1.
2.2.2 Boolean map
A Boolean map (BM) is obtained by removing the feedback path from BCN, i.e., it behaves like a combina-
tional network in Boolean domain.
Definition 2.2. : A BM is a non-feedback form of a BCN which relaxes a requirement for discrete uniform
sampling, represented as:
Y (t) = Γ∗
(
U(t)
)
, (2)
where Γ∗ : {0, 1}α → {0, 1}β is the Boolean operator. t ∈ R+ is a non-negative continuous time index.
Functions (Ψ∗, Γ∗) for BCN and a function Γ∗ for BM are derived from biological information [11].
Therefore, they are assumed to be known for the work in this paper.
3
2.3 Problem formulation in Boolean systems
A faulty BCN can be modeled by considering the faults as separate inputs to the system provided a fault-free
BCN and the probable gene mutations (fault points). The drugs are also treated as external input variables
in the known BCN topology. Without loss of generality, it is assumed that a fault-free BCN shown in (1)
can be converted to define a faulty BCN as:
X(τ) = Ψ̂
(
U(τ), F,D,X(τ − 1)), X(0) = X0,
Y (τ) = Γ̂(U(τ), X(τ)),
(3)
where Ψ̂ : {0, 1}α × {−1, 0, 1}γ × {0, 1}λ × {0, 1}N → {0, 1}N and Γ̂ : {0, 1}α × {0, 1}N → {0, 1}β . Here
(Ψ̂, Γ̂) is a faulty version of a fault-free BCN (Ψ∗,Γ∗). The faults (F ) and drugs (D) are assumed to be
constant over time, hence, the time stamp is not mentioned.
Similarly, a fault-free BM shown in (2) can be converted to define the faulty BM as:
Y = Γ̂(U,F,D), (4)
where Γ̂ : {0, 1}α × {−1, 0, 1}γ × {0, 1}λ → {0, 1}β . Γ̂ is a modified BM after introduction of faults. Since
the time indices of the input and output vectors of the BM are continuous in nature and devoid of causality,
the indices can be omitted for all purposes. Hence (4) and all the subsequent analysis of BM no longer have
a time stamp.
The drugs (D) are inhibitory and are inherently different from the inputs (U). The input U is mostly
not under the control of the therapist for in situ modeling of a gene regulatory system. The inputs can be
growth factors, hormones, oxygen, or different kind of molecular stresses [8], whereas, drugs are user designed
molecules targeted at known locations in Boolean systems. Hence the problem of control design in biological
systems is finding drugs D. In both cases shown in (3) and (4), Ψ̂ and Γ̂ are assumed to be known because
Ψ∗ and Γ∗ are known from their construction.
2.4 Semi-tensor products
For the conversion of logical expression into the linear form, the variables in the logical domain are required
to map in the vector form. Let a vector (delta) set ∆k be defined as ∆k = {δik| i = 1, 2, . . . , k}, where
δik is the i-th column of an identity matrix Ik. A set ∆2 is used to denote the binary values, such that
{1, 0} ∼ {δ12 , δ22} respectively. Therefore, the variables defined in the logical domain are defined in the vector
form given as, {u,y,d} ∈ ∆2. Similarly, a vector set ∆3 is required to show a ternary variable in the vector
form. Therefore, a vector form of fault variable is defined as f ∈ ∆3, where δ13 shows a sa-1 fault, δ23 shows a
sa-0 fault, and δ33 shows a no-fault condition. Although f is not a binary variable, such multi-valued mapping
has been done earlier in the literature [17].
The logical operators Ψ̂ and Γ̂ are converted into linear operators using the semi-tensor product (STP)
approach formulated in [28–32].
Definition 2.3. : Let M be the set of all matrices. Consider a matrix A ∈ Mm×n and a matrix M ∈ Bp×q.
Let c be the least common multiple of n and p. Then the STP of A and B is defined as
An B = (A⊗ Ic/n)(B⊗ Ic/p),
where ⊗ is the Kronecker product of matrices.
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Remark 2.1. : Every matrix product has been assumed to be an STP throughout the paper. Therefore, the
notation “n” is mostly excluded.
For an STP of p k-valued logical variables, a mapping npi=1 : ∆k → ∆kp . For α number of input
variables, an input state U is represented by a vector U = u1 · · ·uα = nαi=1ui. As ui ∈ ∆2, U ∈ ∆2α .
Similarly, the output vector Y ∈ ∆2β , the fault vector F ∈ ∆3γ , and the drug vector D ∈ ∆2λ .
2.5 Structure matrix
A structure matrix is derived from the network structure, and thus represents the characteristics of the
network.
Definition 2.4. : For a logical function σ : Ln → Lm, a matrix Mσ ∈ B2m×2n is defined as a structure matrix
if
σ(x1, . . . , xn) ≡ Mσx1 · · ·xn ∀xi ∈ L and xi ∈ ∆2
The dimensions of a structure matrix depend upon the dimensions of individual xi. In the matrix
form, Mσ = [δ
i1
2m , . . . , δ
i2n
2m ] = δ2m [i1, . . . , i2n ].
3 Methodology
3.1 Structure matrix for faults and drugs
As mentioned in Section 2.3, a fault is modeled as an external input. Therefore, each fault changes the
structure matrix of the network. If a node x is observed (by gene sequencing) to be mutated, its value is
modified to x∗. If the observed mutation is mapped as fault f , then the change in the value of x is given by the
relation in matrix form as x∗ = Mf x f , where {x∗,x} ∈ ∆2, f ∈ ∆3. In this expression, Mf = δ2[1, 2, 1, 1, 2, 2]
is the structure matrix showing the effect of fault for different values of node x. For instance, if the original
value of a node x is 0 (x = δ22) and the fault observed is sa-1 (f = δ
1
3), then x
∗ = Mfδ22δ
1
3 = δ
1
2 . i.e., the
value of x changes to 1 as an effect of fault.
Similarly, the application of an inhibitory drug d blocks the node x by changing its value to 0. When
the drug is not applied, the node x retains its value. In logical form, it is represented as x∗ = x · d¯ [11]. Using
the STP techniques [31], this expression can be written in vector form as x∗ = MD xd, where {x∗,x,d} ∈ ∆2
and MD = δ2[2, 1, 2, 2]. MD shows a structure matrix incorporating the effect of a drug applied at node x.
The derivation of structure matrices Mf and Md are provided in Section A of the Appendix.
The matrices Mf and MD are constant. For every fault f at a node x, x has to be replaced by Mfxf
to obtain a linear form. Similarly, for every inhibitory drug d at a node x, x has to be replaced by MDxd.
3.2 A linear form representation of BM and BCN
Let B be a set of matrices with all binary elements.
3.2.1 Boolean map
A linear form equation for BM is obtained by applying STP properties [31] on (4) to get a linear form
representation as:
Y = ΓUFD, (5)
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where Γ ∈ B2β×2α+λ3γ is a structure matrix of the BM.
3.2.2 Boolean control networks
Similar to BM, STP properties [31] are applied on (3) to get a linear form equation as:
X(τ) = ΨU(τ)FDX(τ − 1),
Y(τ) = ΓU(τ)X(τ),
(6)
where Ψ ∈ B2N×2α+λ+N3γ and Γ ∈ B2β×2α+N are the structure matrices of the BCN.
It is important to modify the system representation for extension applications like improvement in
observability and controllability in such a way that the extensions become computationally tractable. Since
the possible locations of the mutations are known in the BCN, a BCN model is divided into blocks. Block
diagram for a BCN is given in Fig. 1. Such block-wise division is possible with all the BCN and BM.
1
X1X2...Xm 1
X1
X( ) = X1X2...Xm
U( )
Unit 
Delay
X( -1)
L1
m
Ln
m
m
L1
1 1
Ln
X
m
H1
H2
H!
y1
y2
y!
Y( )
1x1
1xn1
mx1
mxnm
Figure 1: Blockwise design of a BCN
The block diagram for the BCN consists of two main parts: primary block (indicated by L matrices)
and the secondary block (indicated by H matrices). The primary block is further divided into sub-blocks,
which are arranged level-wise based on the following rules:
Level 1 contains n1 number of sub-blocks (with structure matrices L
1
i , i = 1, . . . , n1) such that each
sub-block depends on the input (including the state feedback), and only one fault or one drug. x1i shows
the output of block L1i . Level 2 contains n2 number of sub-blocks (with structure matrices L
2
i , i = 1, . . . , n2)
such that each sub-block depends on the input (including the state feedback), only one fault or one drug and
at least one output from level 1 (i.e, at least one of x11, . . . , x
1
n1). Level m contains nm number of sub-blocks
(with structure matrices Lmi , i = 1, . . . , nm) such that each sub-block depends on the input (including the
state feedback), only one fault or one drug and at least one output from level (m − 1) (i.e, at least one of
xm1 , . . . , x
m
nm).
The secondary block is divided into the sub-blocks according to the following rules. Each sub-block
(H1, . . . ,Hβ) depends upon the input and at least one output from level m (i.e. X
1, . . . , Xm). Each sub-block
has a single output, which is one of the primary outputs, and no sub-block has any fault or drug.
The feedback input (X(τ − 1)) is taken from last level (Lm) of the sub-blocks and then it is applied
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to all sub-blocks of the primary block. The total number of sub-blocks in the network is given by:
N =
m∑
i=1
ni + β = γ + λ+ β (7)
This shows that the number of accessible nodes is limited. Since only one fault or one drug per sub-
block is allowed in the block-wise separation, the generation of modified structure matrix for any choice of
faults and drugs becomes straightforward. It also becomes possible to directly access the important internal
nodes (either the node is a mutation site or the node is a target for an available drug). A structure matrix
is derived for a BCN using this block-wise design.
For the BM, the construction is identical except the state feedback link. The structure matrix cal-
culations for BM are provided in Section B the Appendix. A similar process can be followed to obtain the
structure matrices for BCN. The final form of the linear equation of BM can be represented as:
Y = HUFD, (8)
where H ∈ B2β×2α+λ3γ is a structure matrix of the BM. In comparison with (5), Γ = H for the BM structure.
The final form of the linear equation of BCN can be expressed as:
X(τ) = LUFDX(τ − 1)
Y(τ) = HUFDX(τ),
(9)
where L ∈ B2N×2α+λ+N3γ and H ∈ B2β×2α+N are the structure matrices of BCN. (9) shows that effect of
faults and drugs on the next state and on the output vector. The input remains unchanged with the state
transitions; therefore, the time index for the input vector is neglected. In comparison with (6), Ψ = L and
Γ = HW[2λ3γ ,2α]FD for the BCN structure. W[p,q] is a swap matrix of dimensions pq × pq [31].
4 Results
The results for fault analysis and intervention for BM and BCN are derived from their structure matrices
shown in (8) and (9) respectively. The inputs of the biological network are assumed to be experimentally
readable. Therefore, the set of input vectors is assumed to be known experimentally. Before going to the
theorems, let us introduce some variables. F0 represents a fault vector, where all the γ faults are in ‘no-
fault’ state. Hence, F0 = nγj=1δ33 = δ3
γ
3γ . D0 represents a drug vector when no drug is applied. Hence,
D0 = nλj=1δ22 = δ2
λ
2λ . Let F represent the set of all (3γ) fault vectors. However in biology, the number of
hazardous fault vectors is much less than 3γ . Thus, the set of hazardous faults is defined as F̂ ⊆ F . Let
U represent the set of all (2α) input vectors. In the input space, only some inputs are homeostatic inputs,
which are achievable in real biological systems. Thus, Û ⊆ U represents the set of such permissible inputs.
Let D be the set of all (2λ) drugs.
The next section discusses the main results of fault estimation and intervention along with some
corollaries and proposition derived. If the available set of inputs fails to identify a particular fault uniquely,
then it requires designing new output (reporters) to improve the observability. Similarly, if the drugs are
not available for the estimated faults, the improvement in controllability is required. Algorithms 1 and 2
show such a possibility of improvement in observability and controllability of the network. The results are
initially developed for the Boolean map and then extended for the Boolean control networks.
Remark 4.2. : Proofs of the two main theorems are given. All the other proofs are omitted as those proofs
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can be given following the same arguments.
4.1 Boolean map
The network information of BM is available in the structure matrix H represented by (8). Therefore, the
fault analysis and intervention results are derived from the structure matrix H.
Theorem 4.1. : Existence theorem
For a given input vector U˜ ∈ Û in a BM in (8), the existence of fault vector Fi is assured iff
H˜U˜Fi 6= H˜U˜F0,
where H˜ = HW[2λ,2α3γ ]D0 and W[p,q] is a swap matrix of dimensions pq × pq [31].
Proof. : Necessary condition: For the specified input vector U˜ ∈ Û , a null-drug vector D0, and an arbitrary
fault vector Fi in a BM, output Y(U˜,Fi,D0) of the system is given by:
Y(U˜,Fi,D0) = HU˜FiD0 = HW[2λ,2α3γ ]D0U˜Fi = H˜U˜Fi,
where H˜ = HW[2λ,2α3γ ]D0. H˜ ∈ B2β×2α3γ . If a system with structure matrix H is fault-free or under the
influence of null-fault vector F0, the output is given by:
Y(U˜,F0,D0) = HU˜F0D0 = HW[2λ,2α3γ ]D0U˜F0 = H˜U˜F0,
where all input conditions are kept identical. If Y(U˜,Fi,D0) = Y(U˜,F0,D0), the fault vectors Fi and
F0 become indistinguishable. Hence, the necessary condition of the existence of Fi is Y(U˜,Fi,D0) 6=
Y(U˜,F0,D0). Therefore,
H˜U˜Fi 6= H˜U˜F0.
Sufficient condition: Suppose,
H˜U˜Fi 6= H˜U˜F0,
where H˜ = HW[2λ,2α3γ ]D0. H˜ is the modified structure matrix of the BM under null-drug vector D0. The
above inequality trivially establishes that Fi 6= F0. Hence it is sufficient to say that the inequality guaranties
existence of fault vector Fi. This completes the proof.
Corollary 4.1. : For a given fault vector F˜ ∈ F̂ in a BM in (8), there exists an input vector Uj ∈ Û capable
of detecting a fault vector F˜ iff
H˜
′
F˜Uj 6= H˜′F0Uj ,
where H˜
′
= HW[3γ2λ,2α]W[2λ,3γ ]D0.
Proposition 4.2. : For a specified input vector U˜ ∈ Û in BM in (8), a set of fault vectors FU˜ ⊆ F̂ which is
detectable by input vector U˜ is given by
FU˜ = {Fi | H˜U˜Fi 6= H˜U˜F0 ;Fi ∈ F̂},
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where H˜ = HW[2λ,2α3γ ]D0. For existence, FU˜ 6= ∅.
The following results discuss the necessary and sufficient conditions for detecting the existence of a
particular fault using an arbitrary input.
Proposition 4.3. : For a specified fault vector F˜ ∈ F̂ in a BM in (8), a set of input vectors UF˜ ⊆ Û which
can detect the fault vector is given by:
UF˜ = {Ui | H˜
′
F˜Ui 6= H˜′F0Ui ;Ui ∈ Û},
where H˜
′
= HW[3γ2λ,2α]W[2λ,3γ ]D0.
Theorem 4.4. : Uniqueness theorem
For a specific fault F˜ ∈ F̂ in a BM in (8), input U˜ ∈ Û can uniquely identify fault vector F˜ iff
H˜U˜F˜ 6= H˜U˜F0,
and H˜U˜Fj = H˜U˜F0; ∀Fj 6= F˜,Fj ∈ F̂ .
Proposition 4.5. : For a specified fault vector F˜ ∈ F̂ in a BM in (8), a set of input vectors UF˜ ⊆ Û which
can uniquely identify a fault vector F˜ is given by:
UF˜ = {Uj |Uj ∈ Û , H˜UjF˜ 6= H˜UjF0,
H˜UjFk = H˜UjF0 ∀Fk 6= F˜,Fk ∈ F̂}.
Proposition 4.6. : For a given set of input vectors U∗ ⊆ Û , any input vector Ui ∈ U∗ can detect a set of fault
vectors FUi (Proposition 4.2). The set of common fault vectors detectable by a set of given input vectors
can be estimated as:
FU∗ =
ξ⋂
i=1
FUi ; Ui ∈ U∗,
where ξ = card(U∗) is the cardinality of the set U∗.
Proposition 4.7. : Let F̂ be a set of permissible fault vectors for a BM in (8) and a fault vector Fi ∈ F̂ . Let
UFi be a set of input vectors that can detect a fault vector Fi (see Proposition 4.3). Then, an input test set
UT can be generated as:
UT =
µ⋃
i=1
UFi ; Fi ∈ F̂ ,
where µ = card(F̂).
The test set generated by this method is not optimal, but it is useful to know the important homeostatic
inputs and the fault coverage.
Proposition 4.8. : For a test set UT for a BM in (8), fault coverage FC ⊆ F̂ is given by
FC =
ζ⋃
i=1
FUi ,
where ζ = card(UT) and FUi is set of faults detectable by input vector Ui ∈ UT (see Proposition 4.2).
Due to the limited number of homeostatic inputs, many of the fault vectors may remain undetectable
in a real biological system. This affects the fault coverage. The following theorem provides a way to use
multiple input vectors for unique fault detection.
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Corollary 4.2. : Generalized uniqueness
A set of input vectors U∗ ⊆ Û can uniquely determine a fault vector F˜ ∈ F iff FU∗ = {F˜}.
Proposition 4.9. : If FU∗ = ∅, a set of input vectors U∗ cannot detect any fault vector.
Proposition 4.10. : If card(FU∗) 6= 1, a set of input vectors U∗ cannot detect any fault vector uniquely.
Definition 4.1. : If card(FU∗) > 1, a members of the set FU∗ are called indistinguishable faults under a set
of input vectors U∗.
Definition 4.2. : If two fault vectors Fj and Fk are indistinguishable and
H˜UjFi = H˜UjFk ; ∀Uj ∈ U∗ , Fi,Fk ∈ FU∗ , Fi 6= Fk,
then fault vectors Fi and Fk are defined as equivalent. Symbolically Fi ≡ Fk.
In Proposition 4.3, if some fault vector results in UF = ∅ then that fault vector is said to be unde-
tectable. Such faults may not be harmful in the pathways under consideration, but may be harmful in other
dependent pathways. Therefore it is important to detect such faults. In Corollary 4.2, if set FU∗ represents
equivalent fault vectors, then fault detection becomes ambiguous or undetectable. For these conditions, a
new reporter design is necessary. Some faults may not be detectable at primary outputs, but may be de-
tectable at the output of internal blocks. Therefore, observability of faults at every internal node is used to
decide a new reporter.
Let a set of undetectable fault vectors for a set of input vectors U be denoted as FU . Set FU contains
all the faults for which UF = ∅ and the faults which are equivalent. Algorithm 1 results into best possible
reporter(s) for improved fault detection. F ijU indicates a set of detectable faults considering node xij as
‘reporter’. Reporter is an additional input of the network which provides additional information for fault
detection. Selection of each reporter augments the output vector by one. Algorithm 1 results in the set of
best possible reporters, X (best reporter at X (1)). It is clear from Algorithm 1 that the complexity of this
algorithm is O(2
∑m
i=1 ni) or O(2γ+λ) (using (7)). The modular design keeps the structure matrices for the
individual blocks accessible for algebraic manipulation.
Algorithm 1: Improvement in observability
1 Define i := 1, . . . ,m; j := 1, . . . , ni; k = 0 ; X = ∅ ;
2 Augment xij as the (β + 1)
th output ;
3 Compute a set of detectable faults F ijU ⊆ FU ∀i, j (Proposition 4.6) ;
4 while FU 6= ∅ or card(FU ) decreases do
5 (ip, jp) = argmax
∀i,j
card(F ijU ) ;
6 Select x
ip
jp
as reporter ;
7 FU ← FU \ F ipjpU ;
8 F ijU ← F ijU ⊆ FU ;
9 X (k)← xipjp ;
10 k ← k + 1 ;
11 end
12 return X ;
It is possible in principle to put some additional constraints depending on some prior biological knowl-
edge of certain nodes in choosing the best reporter in each iteration. The accessibility of the new reporters
is restricted to the output nodes of the primary sub-blocks only. The number of such sub-blocks is γ + λ,
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which is small compared to the total number of internal nodes in the system keeping the computational
complexity of the algorithm manageable.
Theorem 4.11. : Existence of Intervention
For a BM in (8) with a fault vector F˜ ∈ F̂ and an input vector U˜ ∈ Û , a drug vector Di ∈ D exists if
H˜F˜U˜Di = H˜F0U˜D0,
where H˜ = HW[3γ ,2α], and λ is a number of available drugs.
Proposition 4.12. : For a fault vector F˜ ∈ F and a set of input vectors Û in BM in (8), a set of drug vector
DF˜ which can control the network is given by:
DF˜ = {Dj | H˜F˜U˜Dj = H˜F0U˜D0 ;Dj ∈ D and U˜ ∈ Û}.
Example 4.1. : Consider a BM as shown in Fig. 2. From the network, α = 2, β = 2, γ = 2, λ = 2, m = 2,
f1u1 H1
u2 y1
y2
L1
1
H2
L1
2
L2
1
L2
2
f2
d1
d2
Figure 2: Example 1: Boolean map
n1 = 2, and n2 = 2. For Y = H˜FUD, structure matrix H˜ = HW[9,4] for the system using (8) can be easily
calculated as:
H˜ = δ4
[
4, 4, 4, 4, 4, 4, 4, 4, 3, 4, 3, 4, 4, 4, 4, 4 | 3, 3, 3, 3, 4,
4, 4, 4, 3, 3, 3, 3, 4, 4, 4, 4 | 3, 4, 3, 4, 4, 4, 4, 4, 3, 4, 3, 4, 4,
4, 4, 4 | 4, 4, 2, 2, 4, 4, 4, 4, 3, 4, 1, 2, 4, 4, 4, 4 | 3, 3, 1, 1, 4,
4, 4, 4, 3, 3, 1, 1, 4, 4, 4, 4 | 3, 4, 1, 2, 4, 4, 4, 4, 3, 4, 1, 2, 4,
4, 4, 4 | 4, 4, 4, 4, 4, 4, 4, 4, 3, 4, 3, 4, 4, 4, 4, 4 | 3, 3, 3, 3, 4,
4, 4, 4, 3, 3, 3, 3, 4, 4, 4, 4 | 3, 4, 3, 4, 4, 4, 4, 4, 3, 4, 3, 4, 4,
4, 4, 4
]
If no drugs are applied (i.e., D0 = δ
4
4), the system equation can be written as Y = ĤFU, where
Ĥ = δ4
[
4, 4, 4, 4 | 3, 4, 3, 4 | 4, 4, 4, 4 | 2, 4, 2, 4 |
1, 4, 1, 4 | 2, 4, 2, 4 | 4, 4, 4, 4 | 3, 4, 3, 4 | 4, 4, 4, 4]
Let us assume an input vector U˜ = δ34 . From Proposition 4.2, a set of detectable faults vectors can be
obtained as FU˜ = δ9{2, 4, 5, 6, 8}. Similarly, for a fault vector F˜ = δ49 , using Proposition 4.3, a set of
input vectors which can detect the fault vector F˜ is given by UF˜ = δ4{1, 3}. Suppose a set of fault vectors
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F̂ = δ9{1, 2, 3, 7} is known. Using Theorem 4.4, an input vector U˜ = δ34 can uniquely identify fault F˜ = δ29 .
For the set of given input vectors Û = δ4{1, 2, 3}, the fault coverage (Proposition 4.8) is FC = δ9{2, 4, 5, 6, 8}.
However, for the set of input vectors Û = δ4{2, 4}, fault coverage is FC = ∅. If a given set of fault vectors is
F̂ = δ9{1, 2, 3, 4, 8}, Corollary 4.2 says that using U˜ = δ34 , there is no uniquely detectable fault vectors. In
fact all the detectable fault vectors, i.e, FU˜ = δ9{2, 4, 8} are indistinguishable and δ29 ≡ δ89 .
Improvement in observability : It is evident from the matrix H˜ that fault vectors in the set FU = δ9{1, 3, 7}
are undetectable for control inputs Û . It is required to improve the observability of the network to detect
these faults. Therefore from Algorithm 1, a reporter can be designed as follows:
At node x11 : F11U4 = δ9{1, 3},
at node x22 : F22U2 = δ9{1, 7},
where U2 = δ
2
4 and U4 = δ
4
4 . Therefore, node x
1
1 can be selected as primary reporter. Now, the set of
undetectable faults is reduced to FU = δ79 . Selecting node x22 as secondary reporter guarantees detection of
all faults. However, for constrained input set Û = δ4{1, 3}, observability cannot be improved.
Controllable faults: The faults for which drugs are available are called controllable faults. Assume a set of
input vectors as Û = δ4{1, 3}. Assume the detected faults using fault estimation method as f1 = δ23 (‘stuck-at
0’) and f2 = δ
3
3 (no fault), i.e., the fault vector F˜ = δ
6
9 . For an input vector U˜ = δ
1
4 or U˜ = δ
3
4 :
H˜F˜U˜ = δ4[3, 4, 1, 2].
For a fault-free network without drugs:
H˜F0U˜D0 = H˜δ
9
9U˜δ
4
4 = δ
4
4 .
For D = δ24 : H˜F˜U˜D = H˜δ
9
9U˜δ
4
4 .
i.e., DF˜ = {δ24}, or d1 = δ12 and d2 = δ22 . This shows that for the given fault scenario F˜ = δ69 , only drug d1
is sufficient for nullifying the effect of the fault vector.
Uncontrollable faults: The faults for which drugs are not available are called uncontrollable faults. Let
detected faults using fault estimation method be f1 = δ
2
3 (‘stuck-at 0’) and f2 = δ
2
3 (‘stuck-at 0’). i.e.fault
vector F˜ = δ59 . For input vector U˜ = δ
1
4 or U˜ = δ
3
4 :
H˜F˜U˜ = δ4[3, 3, 1, 1]
H˜δ99U˜δ
4
4 = δ
4
4
For any D : H˜F˜U˜D 6= H˜δ99U˜δ44
Therefore the effects of the fault cannot be controlled with the available set of drugs. 
Improvement in controllability : For Proposition 4.12, if DF˜ = ∅, then a new drug is required such
that it can eliminate the effects of the faults. Let dλ+1 be a new drug. Then,
Dˆ = d1 d2 · · ·dλ+1 = Ddλ+1 = nλ+1j=1dj
Naturally, the effect of faults will be maximum at the downstream protein(s) in the pathways. Although the
secondary block does not have any fault or drug, a new drug can be targetted at the primary output of that
block. These targets facilitate better possibilities of the drug intervention. Therefore, the best possible target
site for the drug is searched from output towards input, level wise. Depending upon the target location of
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the drug, there are two possibilities. (i) Target point is internal node (xij from primary block) of a BM, and
(ii) target point is one of the primary outputs (secondary block) of a BM. For these two cases, similar to
(8), equation of the output can be written as
Y = ĤUFDˆ. (10)
Details of the derivation process are provided in the Appendix (Section C). Algorithm 2 shows the process
of improvement in controllability. However, all faults cannot be controlled with inhibitor type drugs. Some
activator drugs are also required for improved control.
Algorithm 2: Improvement in controllability
1 while DF˜ = ∅ do
2 Derive Y for chosen case ;
3 Find control set DF˜ using Proposition 4.12 ;
4 if DF˜ = ∅ then
5 Change target point ;
6 Repeat all steps ;
7 end
8 if DF˜ 6= ∅ or all target points considered then
9 Stop ;
10 end
11 end
12 return DF˜ ;
4.2 Boolean control network
In (9), the information about network dynamics is shown by structure matrix L. As the secondary block is
fault-free, a structure matrix L alone is sufficient for the fault analysis. The cyclic attractors in the state
transitions of the BCN can be calculated from the diagonal of its structure matrix [31]. The number and
sizes of the attractor cycles in the network change with the fault present. For each input vector and fault
vector, a structure matrix LUF and its corresponding cycles are estimated. Assume that there are s different
attractor cycles in the network. The cycles are numbered in the increasing size of their lengths. The length
of an ith cycle is li. For a cycle of length k, the corresponding diagonal elements of the structure matrix
(LUF)
k become one [31]. Therefore, the diagonal values are used to identify changes in the attractor cycles
for different conditions of the inputs and faults.
Note that A M B is the symmetric difference between the matrices A and B. Tr(A) is the trace of a
matrix A.
Theorem 4.13. : Existence theorem
For a given input U˜ ∈ Û in BCN L (9), the existence of a fault vector Fi is ensured iff
Tr
(
(LU˜Fi)
k M (LU˜F0)
k
)
6= 0 for any k ∈ {l1, l2, . . . , ls},
where LU˜Fi indicates resultant structure matrix L in the presence of input U˜ and fault Fi, lp is the length
of a cycle in BCN LUF
(
lp < lp+1;∀p ∈ {1, . . . , s}
)
, and ls is the length of a largest cycle among all LUF.
Proof. : Necessary condition: For the specified input U˜ ∈ Û , drug D0 and the arbitrary fault Fi in the BCN
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L, the state dynamics of the system is given by:
X(τ) = LU˜FiD0X(τ − 1) = LU˜FiX(τ − 1),
where LU˜Fi = LW[2λ,2α3γ ]D0U˜Fi. LU˜Fi is a matrix of dimension 2
N × 2N , where N is the number of
feedback nodes in the BCN. If the system L is fault-free, the state equation is
X(τ) = LU˜F0D0X(τ − 1) = LU˜F0X(τ − 1),
where all input conditions are kept identical.
LU˜Fi and LU˜F0 represent state transition matrices of the network. The diagonal of matrix (LU˜Fi)
k
represents states involved in cycles of length k and its proper factors. Therefore estimation of Tr
(
(LU˜Fi)
k M
(LU˜F0)
k
)
for increasing k ∈ {l1, l2, . . . , ls} shows mismatch in the cycles. If Tr
(
(LU˜Fi)
k M (LU˜F0)
k
)
= 0,
difference between cycles cannot be estimated, and faults Fi and F0 become indistinguishable. If any value of
k makes Tr
(
(LU˜Fi)
k M (LU˜F0)
k
)
6= 0, fault Fi becomes distinguishable. Therefore, the necessary condition
for existence of fault Fi is Tr
(
(LU˜Fi)
k M (LU˜F0)
k
)
6= 0 for any k ∈ {l1, l2, . . . , ls}.
Sufficient condition: Suppose,
Tr
(
(LU˜Fi)
k M (LU˜F0)
k
)
6= 0 for any k ∈ {l1, l2, . . . , ls},
where LU˜Fi = LW[2λ,2α3γ ]D0U˜Fi. The above inequality states that attractor cycles produced in presence
of fault Fi and that of fault-free network are not same. Therefore it trivially establishes Fi 6= F0. Hence it
is sufficient to say that the inequality guaranties the existence of fault Fi. This completes the proof.
Example 4.2. : Let number of feedback nodes (N) inside the network be 3. Therefore, dimensions of matrix
LU˜Fi or LU˜F0 become 8 × 8. Assume that for some network, known input condition U˜ and fault Fi, the
structure matrix is reduced to
LU˜Fi = δ8[3, 4, 6, 1, 1, 6, 8, 7]
and LU˜F0 = δ8[5, 4, 6, 3, 1, 6, 2, 3]
For k = 1, Tr
(
LU˜Fi M LU˜F0
)
= 0.
For k = 2, Tr
(
(LU˜Fi)
2 M (LU˜F0)
2
)
6= 0. This ensures existence of fault Fi. 
Corollary 4.3. : For a given fault F˜ ∈ F̂ in BCN L (9), there exists an input Uj ∈ Û capable of detecting
fault F˜ iff
Tr
(
(LF˜Uj )
k M (LF0Uj )k
)
6= 0 for any k ∈ {l1, l2, . . . , ls},
where LF˜Uj indicates resultant structure matrix L in presence of input Uj , fault F˜, lp is the length of a
cycle in BCN LFU
(
lp < lp+1;∀p ∈ {1, . . . , s}
)
, and ls is the size of a largest cycle among all LFU.
Assume that the cardinality of the permissible input set Û is κ. A sequence pi of inputs is a subset
of Û . Therefore, card(pi) ≤ κ. The detection of the fault and design of intervention is more reliable when
multiple input vectors are available. Hence, the fault analysis and intervention procedures are derived from
the sequence of inputs.
Corollary 4.4. : For a given fault F˜ ∈ F̂ in BCN L (9), there exists a sequence pi (card(pi) ≤ κ) of inputs
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Uj ∈ Û (j = 1, . . . , κ) capable of detecting fault F˜ iff
Tr
(
κ∏
j=1
LUjF˜ M
κ∏
j=1
LUjF0
)
6= 0,
where LUjF˜ indicates the resultant structure matrix L in presence of input Uj and fault F˜. Note that the
sequence of size card(pi) is sufficient to detect the fault, and full sequence {Uj , j = 1, . . . , κ} may not be
required.
Theorem 4.14. : Uniqueness theorem
For a specific fault F˜ ∈ F̂ in BCN L (9), input U˜ ∈ Û can uniquely identify fault F˜ iff
Tr
(
(LU˜F˜)
k M (LU˜F0)
k
)
6= 0 for any k ∈ {l1, . . . , ls},
and Tr
(
(LU˜Fj )
k M (LU˜F0)
k
)
= 0; ∀k ∈ {l1, l2, . . . , ls};
∀Fj 6= F˜,Fj ∈ F̂ .
Theorem 4.15. : Existence of control
For BCN of (9) with fault vector F˜ ∈ F and sequence pi of control inputs, a drug vector Di ∈ D exists if
Tr
(
1∏
j=card(pi)
LF˜UjDi M
1∏
j=card(pi)
LF0UjD0
)
= 0,
where LF˜ indicates the resultant structure matrix L in presence of fault F˜.
Other result like the generalized uniqueness, improvement in observability, and improvement in con-
trollability can be easily modified for BCN. Thus, those results for BCN are not shown in this manuscript.
Example 4.3. : Boolean equations for p53 pathways are given as [11] :
ATMnext = Wip1
(
ATM +DNA dsb
)
,
p53next = Mdm2
(
ATM +Wip1
)
,
Wip1next = p53,
Mdm2next = ATM
(
p53 +Wip1
)
.
In these pathways, when p53 is ‘active’, it acts as a tumor suppressor (plausible fault location f1) and Mdm2
is one of the target sites for application of drugs (d1). Therefore, α = 1, λ = 1, γ = 1, and N = 4. Structure
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matrix L for the above equations is estimated as shown.
L = δ16
[
10, 10, 2, 2, 10, 10, 2, 2, 9, 9, 5, 5, 9, 9, 5, 5, |14, 10,
6, 2, 14, 10, 6, 2, 13, 9, 5, 5, 13, 9, 5, 5, |12, 12, 4, 4,
12, 12, 4, 4, 11, 11, 8, 8, 11, 11, 8, 8, |16, 12, 8, 4, 16,
12, 8, 4, 15, 11, 8, 8, 15, 11, 8, 8, |10, 10, 2, 2, 12, 12,
4, 4, 9, 9, 5, 5, 11, 11, 8, 8, |14, 10, 6, 2, 16, 12, 8, 4,
13, 9, 5, 5, 15, 11, 8, 8, |10, 10, 2, 2, 10, 10, 2, 2, 9, 9,
13, 13, 9, 9, 13, 13, |14, 10, 6, 2, 14, 10, 6, 2, 13, 9, 13,
13, 13, 9, 13, 13, |12, 12, 4, 4, 12, 12, 4, 4, 11, 11, 16,
16, 11, 11, 16, 16, |16, 12, 8, 4, 16, 12, 8, 4, 15, 11, 16,
16, 15, 11, 16, 16, |10, 10, 2, 2, 12, 12, 4, 4, 9, 9, 13,
13, 11, 11, 16, 16, |14, 10, 6, 2, 16, 12, 8, 4, 13, 9, 13,
13, 15, 11, 16, 16
]
.
p53 having ‘stuck-at 0’ results in proliferation. Therefore, it is important to detect this fault.
Existence theorem:
Case 1 : Let D = D0, U˜ = δ
2
2 , and Fi = δ
2
3 (‘stuck-at 0’). Structure matrix is reduced to
LU˜Fi = δ16[16, 12, 8, 4, 16, 12, 8, 4,
15, 11, 16, 16, 15, 11, 16, 16],
LU˜F0 = δ16[14, 10, 6, 2, 16, 12, 8, 4,
13, 9, 13, 13, 15, 11, 16, 16],
and k = {1}.
For k = 1, Tr
(
LU˜Fi M LU˜F0
)
= 1. This ensures the existence of fault Fi = δ
2
3 .
Case 2 : Let U˜ = δ12 . Keeping other parameters same, structure matrix is reduced to
LU˜Fi = δ16[16, 12, 8, 4, 16, 12, 8, 4,
15, 11, 8, 8, 15, 11, 8, 8],
LU˜F0 = δ16[14, 10, 6, 2, 16, 12, 8, 4,
13, 9, 5, 5, 15, 11, 8, 8],
and k = {1, 7}.
For k = 1, Tr
(
LU˜Fi M LU˜F0
)
= 1. This ensures the existence of fault Fi = δ
2
3 .
Improvement in observability : Improvement is not required as ‘stuck-at 0’ fault is detectable.
Existence of intervention:
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Case 1: Let Uj = δ
2
2 , and fault F˜ = δ
2
3 (‘stuck-at 0’) is detected. Let Di = δ
1
2
LF˜UjDi = δ16[12, 12, 4, 4, 12, 12, 4, 4,
11, 11, 16, 16, 11, 11, 16, 16],
LF0UjD0 = δ16[14, 10, 6, 2, 16, 12, 8, 4,
13, 9, 13, 13, 15, 11, 16, 16],
and k = {1}.
For k = 1, Tr
(
LF˜UjDi M LF0UjD0
)
= 1. Therefore, drug Di = δ
1
2 is not useful.
Case 2: Let Uj = δ
1
2 , and fault F˜ = δ
2
3 (‘stuck-at 0’) is detected. Let Di = δ
1
2
LF˜UjDi = δ16[12, 12, 4, 4, 12, 12, 4, 4,
11, 11, 8, 8, 11, 11, 8, 8],
LF0UjD0 = δ16[14, 10, 6, 2, 16, 12, 8, 4,
13, 9, 5, 5, 15, 11, 8, 8],
and k = {1, 7}.
For k = {1, 7}, Tr((LF˜UjDi)k M (LF0UjD0)k) 6= 0. Therefore, drug Di = δ12 is not useful.
Improvement in controllability : Let the target for new drug d2 be ATM , p53, orWip1. Applying Algorithm 2,
it is observed that target ATM shows some improvement in controllability. When DNA dsb = 0 and p53 is
stuck-at 0, for target ATM , results obtained are as follows:
Assume F˜ = δ23 and Uj = δ
2
2 . Let D3 = δ
1
4 , D2 = δ
2
4 , D1 = δ
3
4 . Therefore,
LF˜UjD3 = δ16[11, 11, 16, 16, 11, 11, 16, 16,
11, 11, 16, 16, 11, 11, 16, 16],
LF˜UjD2 = δ16[12, 12, 4, 4, 12, 12, 4, 4,
11, 11, 16, 16, 11, 11, 16, 16],
LF˜UjD1 = δ16[15, 11, 16, 16, 15, 11, 16, 16,
15, 11, 16, 16, 15, 11, 16, 16],
LF0UjD0 = δ16[14, 10, 6, 2, 16, 12, 8, 4,
13, 9, 13, 13, 15, 11, 16, 16],
and k = {1}.
For k = 1,
Tr
(
LF˜UjD3 M LF0UjD0
)
= 0,
Tr
(
LF˜UjD2 M LF0UjD0
)
= 1,
Tr
(
LF˜UjD1 M LF0UjD0
)
= 0.
Therefore drugs D3 and D1 are useful interventions. In logical equivalence, D3 ∼ (1 1) and D1 ∼ (0 1).
Therefore, only drug d2 is effective. This shows the effectiveness of the method in discarding certain drugs
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and selecting an appropriate therapeutic intervention. A suitable inhibitory drug at ATM may be useful for
the stuck-at 0 fault at p53. This prediction shows that the method may prove to be helpful to decide the
future research towards drugs discovery. 
5 Conclusion
The manuscript describes a linear approach towards fault analysis and intervention in Boolean systems.
The methodology opens up new problems towards fault analysis and intervention in Boolean systems. The
proposed study considers the possibility of multiple faults (mutations) in feedback networks. The method
does not require any test set considering the experimental difficulty in assigning test inputs to biological
networks.
The objective of this work is to obtain the optimal therapeutic intervention with the available input-
output information. In some cases, extra reporters may be required to analyze the mutations. If the none
of drugs are useful from the available set, the improvement in controllability procedure suggests the new
possible targets for the drugs. Although the method is exponential, the drug estimation time is still less than
the treatment time of the patient. Also, the drugs obtained with the proposed work can be used to improve
the lifespan of a patient and save the experimentation cost. Future work can be on the output based fault
identification and control of BCN and the corresponding improvement in observability and controllability
which have been described in this study. Fault analysis and control in the paradigms of asynchronous Boolean
networks and probabilistic Boolean networks can also be taken into consideration in the near future.
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A Preliminaries
A.1 Generalization of matrices
Lemma A.1. : Power reduction matrix
Let a be the column vector of dimension p and A = a1a2 · · ·ak. Then A2 = ΦpA, where
Φp = δp2
[
1, 1 + (p+ 1), 1 + 2(p+ 1), . . . , 1 + (p− 1)(p+ 1)].
Lemma A.2. : Dummy matrix
For column vectors A ∈ Rp and B ∈ Rq, dummy matrix E[p,q] is defined as
E[p,q] = [Ip Ip . . . Ip︸ ︷︷ ︸
q times
],
such that A = E[p,q]BA or A = E[p,q]W[p,q]AB. When p = q, it can be simply represented as E[p].
Definition A.1. (see [31]) If A is a vector of dimension k and B = M1AM2A · · · MqA, then B can be written
in simplified form as B = M∗A, where
M∗ = M1
q∏
i=2
[(
Ik ⊗Mi)Φk
]
.
A.2 Derivation of structure matrix for faults
Assume that the fault is expected to strike at some location x which changes its value to x∗. As x ∈ {0, 1},
x ∈ ∆2. Similarly, x∗ ∈ ∆2. Using STP, this condition can be written in linear form as:
x∗ = Mfx f . (11)
In this expression, Mf ∈ B2×6 is the structure matrix for the fault model. For x = 1 and sa-1 appears at f ,
then x = δ12 and f = δ
1
3 . Hence, x f = δ
1
6 . For this combination of x and f , the value x
∗ = 1. Therefore,
Mfδ
1
6 = δ
1
2 and δ
1
2 gives the first column of the structure matrix Mf . Similarly, Mf can be constructed from
all combinations of x and f . This process gives the structure matrix Mf = δ2[1, 2, 1, 1, 2, 2].
A.3 Derivation of structure matrix for drugs
Assume that a drug d be applied at location x and its value is modified to x∗ on the application of the drug.
The equation for drug intervention in logical form is given as:
x∗ = x ∧ (¬d).
This equation can be written in linear form as:
x∗ = Mcx(Mnd) = Mc(I2 ⊗Mn)xd = MDxd. (12)
In this expression, MD ∈ B2×4 is the structure matrix for the drug intervention, I2 is an identity matrix of
size 2 × 2. Mc = δ2[1, 2, 2, 2] and Mn = δ2[2, 1] are the structure matrices for logical AND operation and
logical NOT operation respectively. These matrices are available in [31]. The structure matrix MD is given
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by:
MD = Mc(I2 ⊗Mn) = δ2[2, 1, 2, 2].
B Derivation of structure matrix for Boolean maps
In the manuscript, Fig. 1 represents the block diagram of Boolean control networks (BCN). For Boolean
Maps (BM), state feedback link is removed. Procedure to estimate structure matrix H in equation (8) of the
manuscript is as follows:
Output at level i (Xi) in primary block is dependent of overall structure matrix of that level (let us
call it Li), and external inputs U , present faults F , and drugs D. In linear form, assume that output Xi
given by:
Xi = LiUFD.
From Fig. 1 in manuscript, equation of individual output for each block j in level i can be written as:
xij = L
i
jUFDX
1 · · · Xi−1, (13)
where i = 1, . . . ,m and j = 1, . . . , ni. Using earlier assumption,
xij = L
i
jUFD(L
1UFD) · · · (Li−1UFD).
From Lemma A.1, (UFD)2 = ΦωUFD and ω = 2
α+λ3γ . Therefore,
xij = L
i
j
i−1∏
k=1
[(
Iω ⊗ Lk
)
Φω
]
UFD = Li∗j UFD, (14)
where Li∗j = L
i
j
i−1∏
k=1
[(
Iω ⊗ Lk
)
Φω
]
.
Output vector at level i is given by
Xi = xi1 x
i
2 · · · xini
= (Li∗1 UFD) (L
i∗
2 UFD) · · · (Li∗niUFD)
= LiUFD, (15)
where Li = Li∗1
ni∏
j=2
[(
Iω ⊗ Li∗j
)
Φω
]
.
The resultant output vector of all the m levels in primary block is STP of the outputs of individual
levels in that block. Therefore,
X = X1X2 · · ·Xm. (16)
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Substituting values using equation (15),
X = (L1UFD)(L2UFD) · · · (LmUFD)
= LUFD, (17)
where L = L1
m∏
j=2
[(
Iω ⊗ Lj
)
Φω
]
. (18)
Primary output vector Y of the BM depends on the secondary level. Inputs of secondary level are
output vector from primary block and primary inputs of BM. Therefore equation of primary output vector
is derived as:
y1 = H1UX.
Substituting X from equation (17),
y1 = H1U(LUFD)
= H∗1UFD, (19)
where H∗1 = H1
(
I2α ⊗ L
)
Φ2α . Similarly, other primary outputs are defined as:
y2 = H
∗
2UFD
...
yβ = H
∗
βUFD.
Output vector Y is given as:
Y = y1 y2 · · · yβ
= (H∗1UFD)(H
∗
2UFD) · · · (H∗βUFD)
= H∗1
β∏
j=2
[(
Iω ⊗H∗j
)
Φω
]
UFD
= HUFD, (20)
where H = H∗1
β∏
j=2
[(
Iω ⊗H∗j
)
Φω
]
.
C Derivation for improvement in controllability in Boolean maps
Let intermediate output xm1 is target location of drug dλ+1. Then x
m
1 is modified as, x
m∗
1 = MDx
m
1 dλ+1.
Therefore from equations (14) and (15), output of level m is given by:
Xm = xm∗1 x
m
2 · · · xmnm
= (MDx
m
1 dλ+1)x
m
2 · · · xmnm
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= (MD L
m∗
1 UFDdλ+1) L
m∗
2 UFD · · · Lm∗nmUFD
= (MD L
m∗
1 UFDˆ) L
m∗
2 UFD · · · Lm∗nmUFD. (21)
Addition of new drug dλ+1 requires to change STP of input UFD as:
UFD = UFd1d2 · · ·dλ
= UFd1d2 · · ·dλ−1E[2]W[2]dλdλ+1
=
(
Iω
2
⊗ E[2]W[2]
)
UFd1d2 · · ·dλ+1
=
(
Iω
2
⊗ E[2]W[2]
)
UFDˆ.
Substituting in equation (21),
Xm = (MD L
m∗
1 UFDˆ) L
m∗
2
(
Iω
2
⊗ E[2]W[2]
)
UFDˆ
· · · Lm∗nm
(
Iω
2
⊗ E[2]W[2]
)
UFDˆ
= (Lˆm∗1 UFDˆ)(Lˆ
m∗
2 UFDˆ) · · · (Lˆm∗nmUFDˆ)
= Lˆm∗1
nm∏
j=2
[(
I2ω ⊗ Lˆm∗j
)
Φ2ω
]
UFDˆ
= LˆmUFDˆ,
where
Lˆm∗i =
MD Lm∗i , i = 1Lm∗i (Iω2 ⊗ E[2]W[2]), otherwise
and Lˆm = Lˆm∗1
nm∏
j=2
[(
I2ω ⊗ Lˆm∗j
)
Φ2ω
]
.
Similarly, any drug location can be selected from outputs of levels in primary block. Generalized form
of output vector for level j for target location xji is given by:
Xj = xj1x
j
2 · · ·xjni
= Lˆj∗1
nj∏
k=2
[(
I2ω ⊗ Lˆj∗k
)
Φ2ω
]
UFDˆ
= LˆjUFDˆ,
where
Lˆl∗k =
MD Ll∗k , l = j and k = iLl∗k (Iω2 ⊗ E[2]W[2]), l 6= j or k 6= i
and Lˆj = Lˆj∗1
nj∏
k=2
[(
I2ω ⊗ Lˆj∗k
)
Φ2ω
]
.
From equation (16), equation of output for primary block is given by:
X = X1X2 · · ·Xm
= (Lˆ1UFDˆ)(Lˆ2UFDˆ) · · · (LˆmUFDˆ)
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= Lˆ1
m∏
j=2
[(
I2ω ⊗ Lˆj
)
Φ2ω
]
UFDˆ
= L̂UFDˆ, (22)
where L̂ = Lˆ1
m∏
j=2
[(
I2ω ⊗ Lˆj
)
Φ2ω
]
. (23)
Let us divide the problem in two parts.
1. The new drug location is selected from primary block: The structure matrix of primary block is rep-
resented as equation (23). Similar to equations (19) and (20), net structure matrix of BN can be
estimated as:
Hˆ∗j = Hj
(
I2α ⊗ L̂
)
Φ2αUFDˆ
Ĥ = Hˆ∗1
β∏
j=2
[(
I2ω ⊗ Hˆ∗j
)
Φ2ω
]
UFDˆ
Y = ĤUFDˆ. (24)
2. The new drug location is selected from primary outputs: If target location is selected one of the primary
outputs yj , the structure matrix L of primary blocks remains unaffected. Therefore from equations (19)
and (20), equation of primary output can be computed as:
Hˆ∗k =
MDHk
(
I2α ⊗ L
)
Φ2α , k = j
Hk
(
I2α ⊗ L
)
Φ2α
(
Iω
2
⊗ E[2]W[2]
)
, otherwise
and
Ĥ = Hˆ∗1
β∏
j=2
[(
I2ω ⊗ Hˆ∗j
)
Φ2ω
]
Y = ĤUFDˆ. (25)
The final form of equations (24) and (25) is shown as equation (10) in the manuscript.
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